Comparing SG&A Expenses: Zoetis Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and Rhythm Pharmaceuticals, Inc. from 2014 to 2023.

Zoetis Inc.: A Steady Climb

Zoetis Inc., a leader in animal health, has consistently maintained high SG&A expenses, reflecting its robust market presence. Over the past decade, its expenses have grown by approximately 31%, peaking at $2.15 billion in 2023. This steady increase underscores Zoetis's strategic investments in marketing and administration to sustain its market leadership.

Rhythm Pharmaceuticals, Inc.: Rapid Growth

In contrast, Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, has seen a dramatic rise in SG&A expenses, surging nearly 96 times from 2014 to 2023. This exponential growth highlights Rhythm's aggressive expansion strategy and its commitment to scaling operations.

Both companies showcase distinct financial strategies, offering insights into their operational priorities and market approaches.